All In Biotech

Drug Trial Radar · NCT05966480

Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus

A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-Controlled Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Dose Levels of ESK-001 in Adult Patients With Systemic Lupus Erythematosus

Last checked: Nov 19, 2026Latest source record: Jul 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 408 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

408

Actual

Start

Jun 26, 2023

Primary completion

Jun 23, 2026

Study completion Sep 1, 2027

Sponsor

Lead sponsor
Alumis IncIndustry
Sponsor type
Industry
First posted
Jul 28, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the clinical efficacy, safety, PK, and PD of multiple dose levels of ESK-001 compared with placebo in adult patients with SLE.

Conditions

  • SLE

Interventions

  • EnvudeucitinibDrug

    Oral tablet

  • PlaceboDrug

    Oral tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To compare the effect on disease activity measured by the proportion of patients achieving British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) response at Week 48 between doses of ESK-001 and placeboTime frame: Week 48

Locations

169 sites in 21 countries. Site status is shown where the registry gives one.

  • Investigator Site #1046

    Anniston, Alabama

  • Investigator Site #1104

    La Jolla, California

  • Investigator Site #1050

    Los Alamitos, California

  • Investigator Site #1168

    Mission Hills, California

  • Investigator Site #1174

    Napa, California

  • Investigator Site #1061

    Upland, California

  • Investigator Site #1048

    Aventura, Florida

  • Investigator Site #1063

    Avon Park, Florida

  • Investigator Site #1176

    Bradenton, Florida

  • Investigator Site #1045

    Clearwater, Florida

  • Investigator Site #1055

    Coral Gables, Florida

  • Investigator Site #1097

    Coral Springs, Florida

  • Investigator Site #1091

    Daytona Beach, Florida

  • Investigator Site #1051

    DeBary, Florida

  • Investigator Site #1087

    Hollywood, Florida

  • Investigator Site #1135

    Kissimmee, Florida

  • Investigator Site #1060

    Miami, Florida

  • Investigator Site #1093

    Miami, Florida

  • Investigator Site #1057

    Miami, Florida

  • Investigator Site #1067

    Miami Lakes, Florida

  • Investigator Site #1090

    Plantation, Florida

  • Investigator Site #1089

    Tampa, Florida

  • Investigator Site #1170

    Atlanta, Georgia

  • Investigator Site #1052

    College Park, Georgia

  • Investigator Site #1204

    Chesterfield, Missouri

  • Investigator site #1209

    Las Vegas, Nevada

  • Investigator Site #1189

    Sparta, New Jersey

  • Investigator Site #1101

    Albuquerque, New Mexico

  • Investigator Site #1058

    Brooklyn, New York

  • Investigator Site #1088

    New York, New York

  • Investigator Site #1175

    Queens, New York

  • Investigator Site #1095

    Charlotte, North Carolina

  • Investigator Site #1056

    Charlotte, North Carolina

  • Investigator Site #1173

    Charlotte, North Carolina

  • Investigator Site #1171

    Philadelphia, Pennsylvania

  • Investigator Site #1062

    Pittsburgh, Pennsylvania

  • Investigator Site #1044

    Memphis, Tennessee

  • Investigator Site #1195

    Carrollton, Texas

  • Investigator Site #1049

    Colleyville, Texas

  • Investigator Site #1071

    Fort Worth, Texas

Showing 40 of 169 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.